Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

+0.53 (+3.64%)
(As of 10:58 AM ET)
Today's Range
50-Day Range
52-Week Range
41,403 shs
Average Volume
519,578 shs
Market Capitalization
$1.22 billion
P/E Ratio
Dividend Yield
Price Target

Deciphera Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
51.8% Upside
$23.00 Price Target
Short Interest
12.26% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.16) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

285th out of 910 stocks

Pharmaceutical Preparations Industry

123rd out of 426 stocks

DCPH stock logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock Price History

DCPH Stock News Headlines

Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Deciphera Pharmaceuticals, Inc. Q4 Loss beats estimates
Deciphera Pharmaceuticals LLC (DCPH)
Deciphera: Upside Potential For The Patient Investor
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$163.36 million
Book Value
$4.38 per share


Free Float
Market Cap
$1.18 billion
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Steven L. Hoerter (Age 53)
    President, CEO & Director
    Comp: $1.24M
  • Mr. Thomas Patrick Kelly J.D.Mr. Thomas Patrick Kelly J.D. (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $778.85k
  • Mr. Daniel C. Martin (Age 49)
    Senior VP & Chief Commercial Officer
    Comp: $711.42k
  • Dr. Matthew L. Sherman M.D. (Age 68)
    Executive VP & Chief Medical Officer
    Comp: $865.62k
  • Dr. Kevin Brodbeck Ph.D.
    Senior VP & Chief Technical Officer
  • Dr. Dashyant Dhanak Ph.D. (Age 63)
    Executive VP & Chief Scientific Officer
  • Jennifer Larson
    Senior Vice President of Finance & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Senior VP & General Counsel
  • Ms. Lisa Amaya Price
    Senior VP & Chief Human Resources Officer
  • Ms. Jama Pitman (Age 44)
    Senior VP & Chief Development Officer

DCPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price target for 2024?

5 analysts have issued 12 month price objectives for Deciphera Pharmaceuticals' shares. Their DCPH share price targets range from $16.00 to $30.00. On average, they anticipate the company's share price to reach $23.00 in the next year. This suggests a possible upside of 51.8% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2024?

Deciphera Pharmaceuticals' stock was trading at $16.13 at the beginning of the year. Since then, DCPH stock has decreased by 6.1% and is now trading at $15.15.
View the best growth stocks for 2024 here

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,060,000 shares, an increase of 7.3% from the March 15th total of 5,650,000 shares. Based on an average trading volume of 540,200 shares, the short-interest ratio is presently 11.2 days. Approximately 12.3% of the company's shares are short sold.
View Deciphera Pharmaceuticals' Short Interest

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our DCPH earnings forecast

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. The firm earned $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative trailing twelve-month return on equity of 49.44%. Deciphera Pharmaceuticals's revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.60) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?
What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

Deciphera Pharmaceuticals (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCPH) was last updated on 4/23/2024 by Staff

From Our Partners